World Sleep Day: What Can Transdermal Delivery Contribute to Sleep Support? (Translation)

Published in the context of World Sleep Day, this article asks how delivery route affects the development of sleep-related products. It distinguishes an everyday relaxation concept from a medicine intended to treat a sleep disorder.

Oral delivery is not the only research route

The original report discusses gastrointestinal absorption and first-pass metabolism in relation to oral melatonin. It cites substantial losses during that process, but this does not establish an equivalent dose or benefit for a patch. Passive transdermal patches also face the skin barrier; changing the delivery route requires its own formulation, exposure and safety assessment.

The night-patch concept described in the source places melatonin and other ingredients in dissolving microcrystal arrays, with the inner wrist and behind the ear illustrated as application locations. These are descriptions of the concept, not instructions for treating insomnia or evidence of an approved transdermal medicine.

Consumer concepts and pharmaceutical research

Both directions draw on CASMN's microneedle platform. The source reports more than 70 patent applications covering design, equipment and manufacturing processes. It also describes research into microneedle formulations of small-molecule medicines for insomnia.

The consumer concept addresses bedtime relaxation, while the pharmaceutical direction requires the evidence and regulatory pathway appropriate to a medicine. Development work is not the same as marketing approval.

Different needs require different evidence

The article argues that a platform can support cosmetics, devices and pharmaceutical research without making these categories interchangeable. Since its establishment in 2018, CASMN has worked on the underlying technology, formulation and production capability.

Beyond a single awareness day

The article closes by presenting transdermal delivery as a development route worth investigating, rather than a universal replacement for oral products. Persistent sleep difficulties call for appropriate professional assessment, not reliance on a product-format claim.